文献速递妇产影像US

双胎妊娠11-13周母体因素和生物标志物预测子痫前期:EVENTS试验数据

Prediction of pre-eclampsia in twin pregnancy by maternal factors and biomarkers at 11-13 weeks' gestation: data from EVENTS trial.
PubMed 文献 · Ultrasound Obstet Gynecol · 2021-01-01

基于EVENTS试验1798例双胎妊娠数据验证既往双胎子痫前期筛查模型,并联合另一数据集共3938例比较双胎与单胎的生物标志物分布,建立新模型。结果显示母体因素联合MAP、UtA-PI和PlGF筛查效果最佳,假阳性率10%时,<32周子痫前期检出率从30.6%提高至86.4%,<37周从24.9%提高至41.1%。

要点

  • 双胎妊娠11-13周筛查子痫前期可沿用既往基于母体因素和病史的先验模型。
  • 计算后验风险需按分娩孕周采用双胎MAP、UtA-PI和PlGF新的log10 MoM值分布。
  • 母体因素联合MAP、UtA-PI和PlGF筛查效果最佳,优于母体因素单独筛查。

核心结论

  • 双胎妊娠评估子痫前期风险可沿用既往基于母体特征和病史的先验模型,但计算后验风险需按分娩孕周采用双胎UtA-PI、MAP和PlGF新的log10 MoM值分布。

研究设计与样本

  • 研究采用两个前瞻性非干预多中心筛查研究数据集,均为双胎妊娠11+0至13+6周。
  • 第一个数据集来自EVENTS试验,共1798例双胎妊娠,其中168例(9.3%)发生子痫前期。
  • 第二个数据集来自既往报告的双胎妊娠生物标志物分布研究,合并后共3938例,其中339例(8.6%)发生子痫前期,253例(6.4%)在<37周分娩合并子痫前期。
  • 采用竞争风险模型估算个体化风险,以检出率和ROC曲线下面积评估筛查性能。

诊断标准与关键数值

  • 既往模型验证中,校准图显示预测风险与观察子痫前期发生率高度一致,<32周子痫前期校准斜率和截距分别为0.827和0.009,<37周分别为0.942和-0.207。
  • 在双胎妊娠合并子痫前期者中,MAP、UtA-PI和PlGF在较早孕周比单胎更具判别力,在较晚孕周判别力较低;PAPP-A在子痫前期与未受影响妊娠间差异很小。
  • 假阳性率10%时,母体因素单独筛查对<32周分娩合并子痫前期的检出率为30.6%,联合筛查(母体因素+MAP+UtA-PI+PlGF)提高至86.4%。
  • 假阳性率10%时,母体因素单独筛查对<37周分娩合并子痫前期的检出率为24.9%,联合筛查为41.1%。

临床应用与阅片要点

  • 双胎妊娠11-13周筛查子痫前期时,可沿用既往基于母体特征和病史的先验模型,但后验风险计算需采用双胎专用的MAP、UtA-PI和PlGF的log10 MoM值分布。
  • 联合母体因素、MAP、UtA-PI和PlGF筛查对早产子痫前期(<32周)检出率较高,对<37周子痫前期检出率相对有限。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: First, to validate a previously developed model for screening for pre-eclampsia (PE) by maternal characteristics and medical history in twin pregnancies; second, to compare the distributions of mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI), serum placental growth factor (PlGF) and serum pregnancy-associated plasma protein-A (PAPP-A) in twin pregnancies that delivered with PE to those in singleton pregnancies and to develop new models based on these results; and, third, to examine the predictive performance of these models in screening for PE with delivery at < 32 and < 37 weeks' gestation.

METHODS: Two datasets of prospective non-intervention multicenter screening studies for PE in twin pregnancies at 11 + 0 to 13 + 6 weeks' gestation were used. The first dataset was from the EVENTS (Early vaginal progesterone for the preVention of spontaneous prEterm birth iN TwinS) trial and the second was from a previously reported study that examined the distributions of biomarkers in twin pregnancies. Maternal demographic characteristics and medical history from the EVENTS-trial dataset were used to assess the validity of risks from our previously developed model. The combined data from the first and second datasets were used to compare the distributional properties of log10 multiples of the median (MoM) values of UtA-PI, MAP, PlGF and PAPP-A in twin pregnancies that delivered with PE to those in singleton pregnancies and develop new models based on these results. The competing-risks model was used to estimate the individual patient-specific risks of delivery with PE at < 32 and < 37 weeks' gestation. Screening performance was measured by detection rates (DR) and areas under the receiver-operating-characteristics curve.

RESULTS: The EVENTS-trial dataset comprised 1798 pregnancies, including 168 (9.3%) that developed PE. In the validation of the prior model based on maternal characteristics and medical history, calibration plots demonstrated very good agreement between the predicted risks and the observed incidence of PE (calibration slope and intercept for PE < 32 weeks were 0.827 and 0.009, respectively, and for PE < 37 weeks they were 0.942 and -0.207, respectively). In the combined data, there were 3938 pregnancies, including 339 (8.6%) that developed PE and 253 (6.4%) that delivered with PE at < 37 weeks' gestation. In twin pregnancies that delivered with PE, MAP, UtA-PI and PlGF were, at earlier gestational ages, more discriminative than in singleton pregnancies and at later gestational ages they were less so. For PAPP-A, there was little difference between PE and unaffected pregnancies. The best performance of screening for PE was achieved by a combination of maternal factors, MAP, UtA-PI and PlGF. In screening by maternal factors alone, the DR, at a 10% false-positive rate, was 30.6% for delivery with PE at < 32 weeks' gestation and this increased to 86.4% when screening by the combined test; the respective values for PE < 37 weeks were 24.9% and 41.1%.

CONCLUSIONS: In the assessment of risk for PE in twin pregnancy, we can use the same prior model based on maternal characteristics and medical history as reported previously, but in the calculation of posterior risks it is necessary to use the new distributions of log10 MoM values of UtA-PI, MAP and PlGF according to gestational age at delivery with PE. © 2020 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Benkő Z, Wright A, Rehal A, et al. Prediction of pre-eclampsia in twin pregnancy by maternal factors and biomarkers at 11-13 weeks' gestation: data from EVENTS trial. Ultrasound Obstet Gynecol. 2021. PMID: 33142361. doi:10.1002/uog.23531

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。